Research overview: the unregulated GS-441524 movement and FIP treatment access

Before legal antiviral products existed, owners desperate to save cats with FIP obtained unregulated GS-441524 through informal networks and online communities, often coordinating dosing with sympathetic veterinarians despite regulatory and quality-control uncertainties. This grassroots movement saved many cats and generated large bodies of real-world outcome data, while raising questions about drug purity, legality, and the ethics of veterinary involvement. This overview compiles accounts and clinical commentary rather than one source, describing how the gap between scientific breakthrough and regulatory approval drove owner-led access, why the experience accelerated eventual legitimate availability of remdesivir and related products, and how the FIP story illustrates the tension between rapid translation of research and the regulatory frameworks governing veterinary therapeutics.